PT  - JOURNAL ARTICLE
AU  - Tareef Fadhil Raham
TI  - Influence of Malaria Edemicity and Standardized TB Prevalence to BCG Coverage on Covid-19 Mortality
AID  - 10.1101/2020.09.09.20191684
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.09.20191684
4099  - http://medrxiv.org/content/early/2020/09/12/2020.09.09.20191684.short
4100  - http://medrxiv.org/content/early/2020/09/12/2020.09.09.20191684.full
AB  - Background Regarding SARS-CoV-2 it is well known that a substantial percentage of adult population cannot get infected if exposed to this novel coronavirus. Several studies give primary indication of the possible role of preexisting immunity whether cross immunity or not. Possible role of latent TB and BCG and malaria have been already suggested to create innate cross heterogeneous immunity. We look for influence of these factors on Covid-19 mortality in malarious countries.Material and methods 80 malarious countries are enrolled in this study. Hierarchical multiple regression type of analyses is used for data analyses. TB prevalence/ 100,000 population standardized to BCG coverage rates is taken as direct factor in the test. Malaria incidence /1000 population is considered as intermediate factor and the outcome is COVID-19 mortality/ 1 million (M) population.Results TB prevalence is associated with reduced COVID-19 mortality and malaria have an additional effect in reducing COVID-19 mortality. The results show with robust statistical support that TB prevalence was also associated with reduced COVID-19 mortality with additional effect that is also observed in TB and BCG coverage rate.Conclusions Malaria and standardized TB prevalence are statistical significant factors predicting COVID-19 mortality in negative associations.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno funding receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data are publicly available . Patients were not involved.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are publicly available. links to publicly accessed data are included within the manuscript